secwatch.observer — SEC 8-K summary
======================================

Issuer:     IO Biotech, Inc. (IOBTQ)
CIK:        0001865494
Form:       8-K
Filed at:   2022-05-13T23:59:59+00:00
Accession:  0001193125-22-150146
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CFO Keith Vendola departs; Brian Burkavage appointed Chief Accounting Officer
-----------------------------------------------------------------------------

- Keith Vendola terminated as CFO by mutual agreement effective May 9, 2022; no disagreement with company or board.
- CEO Mai-Britt Zocca will serve as Principal Financial Officer until CAO appointment.
- Brian Burkavage, previously VP of Finance, appointed Chief Accounting Officer effective May 12, 2022.
- Burkavage was Controller at Passage BIO (2020-2021) and Director of FP&A at Aclaris Therapeutics (2017-2020).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1865494/000119312522150146/0001193125-22-150146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1865494/000119312522150146/d339835d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-150146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer